*** Strong Bullish Momentum Confirmed (Chart + Data Match)
Stock recently made a fresh breakout near the ₹140 zone
Trading near 52-week high (₹133–₹137 zone earlier)
Clear Higher High – Higher Low structure → Strong uptrend continuation
🟢 Demand Zone: ₹128 – ₹132
🟡 Retracement Zone: Perfect bounce area
🔴 Premium Zone: Above ₹140 (current price area)
Institutions likely active near the demand zone
About the Company
Gaudium IVF and Women Health Limited is one of India's leading IVF (In-Vitro Fertilization) chains, founded in March 2015 by Dr. Manika Khanna and Dr. Peeyush Khanna in Delhi. It is a healthcare services company focused on fertility treatment, women's health, and assisted reproductive technology (ART).
The company operates through a Hub-and-Spoke model — 7 Hubs (full-service IVF centers) and 28 Spokes (strategic alliances with infertility experts) across 9 states in India, totaling 30+ locations.
It was successfully listed on NSE & BSE on February 27, 2026, at an issue price of ₹79/share.
CEO & Founder — Dr. Manika Khanna
Detail Information
Designation Chairperson & Managing Director (CMD)
Education MBBS (Gold Medallist), MD in Obstetrics & Gynecology — Maharaja Sayajirao University of Baroda
Specialization Advanced Gynecological Endoscopic Surgery — Kiel, Germany
Experience 16+ years in IVF treatment
Awards Delhi Ratna Award (2008), Women Excellence Award (2016), Oxford Academy UK — Medical Science Global Women's Health (2021), BusinessWorld Healthcare Personality of the Year — Women (2017)
Dr. Manika Khanna is the primary driving force behind Gaudium IVF. She is not just the clinical head but also the strategic and business leader of the company. She was also the selling shareholder in the IPO's Offer for Sale, divesting ~94.93 lakh shares worth ₹75 crore
Business Model
Gaudium IVF operates a diversified, patient-centric revenue model:
Revenue Stream Contribution
IVF Treatment 64%
Pharmacy 31%
Hospital Services 4%
The pharmacy segment grew from just 0.50% in FY23 to 28.85% in FY25 — a massive margin-enhancing shift.
Patient Journey: Lead generation → Consultation → Stimulation → OPU (Ovum Pick-Up) → Embryo Transfer → Post-care. Approximately 70% of the package amount is collected by the OPU stage, ensuring strong cash flow visibility.
Key Differentiators:
• GAAT (Gaudium Advanced Analysis and Treatment) — proprietary genome-based personalization system
• 58.74% IVF success rate (as of Sept 2025) vs. industry average
• Focus on complex/high-risk IVF cases (patients with 10–15 failed cycles)
• ₹7.39 crore invested in R&D as of March 2025
• Average Revenue per Patient: ₹3.55 lakh
• IVF in India costs ₹3–4 lakh vs. ₹18 lakh in the US — strong medical tourism advantage
Shareholding Pattern (Latest: FY27 Q1)
Category Holding %
Promoters 71.29%
FII (Foreign Institutional) 3.02%
DII (Domestic Institutional) 2.22%
Public 16.78%
Others 6.69%
>> Promoter holding is strong at 71.29% — zero pledging reported
Growth Strategy & Expansion Plans Year Expansion Plan FY27 - 3 new hubs launching (2 in Delhi/NCR, 1 in Nagpur) FY28 8 new centres planned FY29 1 additional centre
360° Customer Acquisition Strategy:
1. Digital Marketing (50%) — performance marketing, Tier II/III city targeting
2. Word of Mouth (30%) — strong patient & doctor networks
3. PR (10%) — media, celebrity partnerships
4. Brand Building (10%) — ATL/BTL advertising
Key Growth Drivers:
1. 13% national infertility rate — 27.5 million couples affected
2. India's Total Fertility Rate fell to 1.9 (below the replacement level of 2.1)
3. Technological advances — AI embryo selection, time-lapse incubators, genetic testing (PGT)
4. Expansion into Tier 2 & Tier 3 cities
5. Medical tourism — India's IVF costs are 80% cheaper than the US
6. ART (Regulation) Act providing regulatory clarity
Debt/Equity 0.52 (manageable)
Sector Tailwind Strong — 13%+ CAGR IVF market
Expansion Aggressive — 12 new centres by FY29
“Strong breakout stock with solid fundamentals like 25% ROE & expansion plans. Brokers positive but valuation expensive. Best strategy: Buy on dips, not at highs. Momentum intact with upside potential.”
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.